These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 25214517)
21. HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients. Salmon D; Bani-Sadr F; Gilbert C; Rosenthal E; Valantin MA; Simon A; Neau D; Morlat P; Loko MA; Wittkop L; Dabis F; J Clin Virol; 2015 Dec; 73():32-35. PubMed ID: 26528903 [TBL] [Abstract][Full Text] [Related]
22. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C. Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387 [TBL] [Abstract][Full Text] [Related]
23. Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4. Martín-Carbonero L; Puoti M; García-Samaniego J; De Luca A; Losada E; Quinzan G; Bruno R; Mariño A; González M; Núñez M; Soriano V J Viral Hepat; 2008 Oct; 15(10):710-5. PubMed ID: 18637070 [TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy. Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957 [TBL] [Abstract][Full Text] [Related]
25. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART. Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P; Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225 [TBL] [Abstract][Full Text] [Related]
26. Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women. Nasta P; Maida I; Cattelan AM; Pontali E; Angeli E; Giralda M; Verucchi G; Caputo A; Iannacone C; Puoti M; Carosi G J Womens Health (Larchmt); 2015 Feb; 24(2):159-64. PubMed ID: 25682817 [TBL] [Abstract][Full Text] [Related]
27. Boceprevir, peginterferon and ribavirin for acute hepatitis C in HIV infected patients. Hullegie SJ; Claassen MA; van den Berk GE; van der Meer JT; Posthouwer D; Lauw FN; Leyten EM; Koopmans PP; Richter C; van Eeden A; Bierman WF; Newsum AM; Arends JE; Rijnders BJ J Hepatol; 2016 Apr; 64(4):807-12. PubMed ID: 26689767 [TBL] [Abstract][Full Text] [Related]
28. [HCV reinfection after liver transplantation - management and first experiences with telaprevir-based triple therapy]. Herzer K; Papadopoulos-Köhn A; Timm J; Paul A; Jochum C; Gerken G Dtsch Med Wochenschr; 2013 Sep; 138(36):1759-64. PubMed ID: 24002874 [TBL] [Abstract][Full Text] [Related]
29. Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study. Dieterich D; Rockstroh JK; Orkin C; Gutiérrez F; Klein MB; Reynes J; Shukla U; Jenkins A; Lenz O; Ouwerkerk-Mahadevan S; Peeters M; De La Rosa G; Tambuyzer L; Jessner W Clin Infect Dis; 2014 Dec; 59(11):1579-87. PubMed ID: 25192745 [TBL] [Abstract][Full Text] [Related]
30. Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon alpha-2b+ full-course vs. 16-week delayed ribavirin. Bräu N; Rodriguez-Torres M; Prokupek D; Bonacini M; Giffen CA; Smith JJ; Frost KR; Kostman JR Hepatology; 2004 Apr; 39(4):989-98. PubMed ID: 15057903 [TBL] [Abstract][Full Text] [Related]
31. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients. Ramos B; Núñez M; Rendón A; Berdún MA; Losada E; Santos I; Echevarría S; Ocampo A; Miralles C; Arazo P; Barreiro P; Romero M; Labarga P; Guardiola JM; Garcia-Samaniego J; Soriano V J Viral Hepat; 2007 Jun; 14(6):387-91. PubMed ID: 17501758 [TBL] [Abstract][Full Text] [Related]
32. Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C. Belperio PS; Hwang EW; Thomas IC; Mole LA; Cheung RC; Backus LI Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1021-7. PubMed ID: 23524130 [TBL] [Abstract][Full Text] [Related]
33. Boceprevir and telaprevir-based regimens for the treatment of hepatitis C virus in HIV/HCV coinfected patients. Beste LA; Green PK; Ioannou GN Eur J Gastroenterol Hepatol; 2015 Feb; 27(2):123-9. PubMed ID: 25503739 [TBL] [Abstract][Full Text] [Related]
34. Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin. Soriano V; Miralles C; Berdún MA; Losada E; Aguirrebengoa K; Ocampo A; Arazo P; Cervantes M; de los Santos I; San Joaquín I; Echeverria S; Galindo MJ; Asensi V; Barreiro P; Sola J; Hernandez-Burruezo JJ; Guardiola J; Blanco F; Martin-Carbonero L; García-Samaniego J; Nuñez M; Antivir Ther; 2007; 12(4):469-76. PubMed ID: 17668555 [TBL] [Abstract][Full Text] [Related]